Ocuphire Pharma Investor Day Presentation Deck
DR
DME
Clinical Unmet Need in Diabetic Retinal Diseases
Increasing Prevalence of DR with No Early Intervention Options
• DR/DME are major causes of vision loss in
working aged adults
The Problem
• Diabetic population expected to increase
dramatically worldwide
●
●
Approved therapies for DR are effective but
require IVT injection
DR patients are not routinely treated with
approved injectable anti-VEGF drugs until
they develop center-involved DME or PDR
DR progresses resulting in vision loss
Early, noninvasive intervention targeting
DR represents a therapeutic unmet need
Growing Incidence of Diabetes and DR
Diabetes
34 M US
>450 M WW
7 M US
>150 M WW
DR/DME affects about 1 in 4 people
with type 1 and type 2 diabetes¹
DR
24
American Diabetes Association; International Diabetes Federation; Healthline
Das UN. DME, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci. 2016;12(5):1142-1157. doi:10.5114/aoms.2016.61918
Ocuphire
PHARMAView entire presentation